Clinical Trial Update: RCT of Tocilizumab for Anti-MDA5+DM [NA]

View source ↗

Summary

A randomized controlled trial evaluating tocilizumab for Anti-MDA5-positive dermatomyositis is currently recruiting at Peking Union Medical College Hospital.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Dermatomyositis | NA | Status: RECRUITING